AEGiS-ATN: Nevirapine Patient Assistance Program: Model for Better Administration?

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Nevirapine Patient Assistance Program: Model for Better Administration?

AIDS TREATMENT NEWS Issue #385, November 22, 2002
Comment by John S. James

The new Boehringer Ingelheim patient assistance program for nevirapine for U.S. residents may be an improvement over other programs, in that it streamlines the paperwork and administration. A patient applies once for a year -- by sending a one-page application plus proof of income. A new foundation set up by Boehringer Ingelheim promises a response in two days. Then the patient picks up the drug four times per year at the doctor's office. At the end of the year the patient can apply again for the next year -- and will be sent a reminder to do so.

It seems that the doctor doesn't have to do burdensome paperwork for this program -- only write the prescription, and hold the medicine package for the patient four times per year. This should prevent a major problem for medical staffs, and open the program to more people in public clinics.

However, the income eligibility level for nevirapine is calculated differently than for the company's non-HIV drugs, for reasons that are not clear. What should be done instead is to have uniform income levels but allow patients to deduct out-of-pocket medical expenses in meeting the income requirement.

A bigger problem may be in the interpretation of, "Be ineligible for prescription assistance through Medicaid." If a patient is eligible for Medicaid prescription coverage but that coverage does not include nevirapine, does he or she just have to do without AIDS treatment? No one eligible for Medicaid could pay for this drug out of pocket, and public programs are increasingly running out of money.

We believe the important advance here is that this program could work efficiently. Many other patient-assistance programs seem designed to get the drug only to those who have enough of a support network around them to possibly make an issue in the media if they don't get treated, while limiting expenses by denying treatment to others. The very paperwork used to restrict those programs makes them expensive to run. But this new program could control costs by delivering drug efficiently to patients who have no other way to get it, at little cost to the company.

For more information or to apply, visit: http://us.boehringer-ingelheim.com/about/ philanthropy/Patient_Assistance_Program.html (note: there is no carriage return or space between the two lines above).
021122
ATN38502

Copyright © 2002 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .